This company has been marked as potentially delisted and may not be actively trading. Millendo Therapeutics (MLND) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock MLND vs. SBTX, UPB, SION, PRTA, KURA, COGT, AKBA, STOK, GHRS, and TYRAShould you be buying Millendo Therapeutics stock or one of its competitors? The main competitors of Millendo Therapeutics include Silverback Therapeutics (SBTX), Upstream Bio (UPB), Sionna Therapeutics (SION), Prothena (PRTA), Kura Oncology (KURA), Cogent Biosciences (COGT), Akebia Therapeutics (AKBA), Stoke Therapeutics (STOK), GH Research (GHRS), and Tyra Biosciences (TYRA). These companies are all part of the "medical" sector. Millendo Therapeutics vs. Silverback Therapeutics Upstream Bio Sionna Therapeutics Prothena Kura Oncology Cogent Biosciences Akebia Therapeutics Stoke Therapeutics GH Research Tyra Biosciences Silverback Therapeutics (NASDAQ:SBTX) and Millendo Therapeutics (NASDAQ:MLND) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, community ranking, analyst recommendations, dividends, earnings, media sentiment and risk. Do institutionals & insiders believe in SBTX or MLND? 74.9% of Silverback Therapeutics shares are owned by institutional investors. 34.4% of Silverback Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has more risk and volatility, SBTX or MLND? Silverback Therapeutics has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500. Comparatively, Millendo Therapeutics has a beta of 0.48, indicating that its share price is 52% less volatile than the S&P 500. Does the media favor SBTX or MLND? In the previous week, Silverback Therapeutics' average media sentiment score of 0.00 equaled Millendo Therapeutics'average media sentiment score. Company Overall Sentiment Silverback Therapeutics Neutral Millendo Therapeutics Neutral Does the MarketBeat Community believe in SBTX or MLND? Silverback Therapeutics received 18 more outperform votes than Millendo Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformSilverback TherapeuticsOutperform Votes1856.25% Underperform Votes1443.75% Millendo TherapeuticsN/AN/A Which has better earnings and valuation, SBTX or MLND? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSilverback TherapeuticsN/AN/A-$89.48M-$2.42-5.69Millendo TherapeuticsN/AN/A-$36.41MN/AN/A Is SBTX or MLND more profitable? Silverback Therapeutics' return on equity of -29.62% beat Millendo Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Silverback TherapeuticsN/A -29.62% -28.20% Millendo Therapeutics N/A -91.03%-72.44% SummarySilverback Therapeutics beats Millendo Therapeutics on 6 of the 7 factors compared between the two stocks. Get Millendo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MLND and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MLND vs. The Competition Export to ExcelMetricMillendo TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$147.77M$6.70B$5.46B$7.72BDividend YieldN/A3.13%5.42%4.25%P/E RatioN/A7.2722.4418.49Price / SalesN/A239.68392.61101.64Price / CashN/A65.8538.1834.62Price / Book4.366.306.674.19Net Income-$36.41M$143.17M$3.22B$248.18M Millendo Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MLNDMillendo TherapeuticsN/A$7.76-3.6%N/A+119.2%$147.77MN/A0.0012Gap DownSBTXSilverback TherapeuticsN/A$14.88flatN/A+64.9%$536.54MN/A-6.1583High Trading VolumeUPBUpstream BioN/A$9.90+2.0%$56.50+470.7%N/A$525.84M$2.37M0.0038News CoveragePositive NewsSIONSionna TherapeuticsN/A$11.66+3.2%$38.50+230.2%N/A$514.49MN/A0.0035Gap UpPRTAProthena3.348 of 5 stars$9.52+2.4%$55.00+477.8%-53.5%$512.43M$135.16M-4.14130KURAKura Oncology4.3793 of 5 stars$6.19+0.2%$25.50+312.0%-67.3%$502.04M$53.88M-2.63130Upcoming EarningsPositive NewsCOGTCogent Biosciences2.3587 of 5 stars$4.37+1.6%$14.43+230.2%-22.9%$498.66MN/A-1.7780Positive NewsAKBAAkebia Therapeutics3.5722 of 5 stars$2.09+1.0%$6.50+211.0%+77.6%$494.90M$160.18M-9.11430Analyst DowngradePositive NewsSTOKStoke Therapeutics3.5023 of 5 stars$9.14+6.1%$24.67+170.0%-21.4%$494.54M$36.56M-4.35100Upcoming EarningsPositive NewsGHRSGH Research1.847 of 5 stars$9.32+1.6%$30.86+231.1%-9.3%$491.67MN/A-11.9610Upcoming EarningsNews CoverageTYRATyra Biosciences1.8769 of 5 stars$9.16+1.1%$30.83+236.5%-35.9%$486.36MN/A-5.6920Positive News Related Companies and Tools Related Companies SBTX Alternatives UPB Alternatives SION Alternatives PRTA Alternatives KURA Alternatives COGT Alternatives AKBA Alternatives STOK Alternatives GHRS Alternatives TYRA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MLND) was last updated on 4/28/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | Sponsored‘Wheels Are Falling Off’ the U.S. Stock MarketThe last time the U.S. economy looked like this, stocks didn't move for 16 years... And many investors lost...Stansberry Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredIt’s absolute chaos in Silicon Valley right now…If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Millendo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Millendo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MLND Stock Free MLND Stock Alerts